In short
Clinical trials of 99MTC-EUK-(SO3)CY5-MAS3 are studying how this imaging-related substance performs in people with prostate cancer. The trial aims to check whether it can show lesion-specific uptake, which means whether it is seen in cancer spots. The target group is adults with prostate cancer in a small Phase 1/2 study.
Key points
- Clinical trials of 99MTC-EUK-(SO3)CY5-MAS3 are being done in people with prostate cancer. The main goal is to see whether the study substance shows lesion-specific uptake, meaning whether it appears in cancer spots. The trial is a small Phase 1/2 interventional study with 13 planned participants. Its status is Authorised. The key result being measured is the presence of uptake in prostate cancer lesions.
Trial overview
The clinical trial identified as 2023-505453-40-00 is studying 99MTC-EUK-(SO3)CY5-MAS3 in people with prostate cancer. The trial title is DUAL, and it is an interventional study, which means the research team gives the study intervention and then measures the results.
The source data also lists the intervention as “hybrid PSMA (INTRAVENOUS ADMINISTRATION),” but it does not provide more detail beyond that name.
Who can participate
The target population for this study is people with prostate cancer. The source information does not give more detailed inclusion or exclusion rules, so the main known requirement is the disease being studied.
What is being measured
The main outcome is the presence of lesion-specific uptake of 99mTc-hPSMA by prostate cancer. In simple terms, the study is checking whether the test substance is seen in the cancer spots, which can help show if the target areas are detected clearly.
The brief summary says the purpose is to confirm lesion-specific uptake of 99mTc-hPSMA by prostate cancer. This makes the imaging result the central focus of the trial.
Trial phase and design
This study is in Phase 1/2. Phase 1/2 studies are early clinical studies that often combine first testing in people with an early look at whether the study approach gives useful results.
The trial is listed as interventional, meaning the researchers actively apply the study intervention rather than only observing what happens naturally.
Trial status and size
The trial status is Authorised. This means the study has been approved to proceed according to the source record.
The planned enrollment is 13 participants, so this is a small study. Small early studies are often used to gather initial information before larger research is done.
Patient terms explained
Uptake means how much of the study substance is taken into a body area or seen in a scan. Lesion means an abnormal area, such as a tumor spot.
Primary outcome is the main result the researchers want to measure. In this trial, that main result is whether 99MTC-EUK-(SO3)CY5-MAS3 shows up in the prostate cancer lesions.
Enrollment is the planned number of people who will join the study. Here, the planned number is 13.